Evidence map›Paper›PMID 26858355›Full record

Trial reportHaematologica2016

Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: final results of a phase II study conducted by the Fondazione Italiana Linfomi.

Stefano Sacchi, Raffaella Marcheselli, Alessia Bari, Gabriele Buda, Anna Lia Molinari, Luca Baldini, Daniele Vallisa, Marina Cesaretti, Pellegrino Musto, Sonia Ronconi and 10 more

Open access · goldAbstract readClinical Trial, Phase IILetterMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Haematologica, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.7field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 20 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Sample Size Requirements for Calibrated Approximate Credible Intervals for Proportions in Clinical Trials.International journal of environmental research and public health · 2021
    Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 12 institutions in 1 country.

Stefano SacchiDepartment of Diagnostic, Clinical and Public Health Medicine University of Modena and Reggio Emilia, Rimini stefano.sacchi@unimore.it.
Raffaella MarcheselliDepartment of Diagnostic, Clinical and Public Health Medicine University of Modena and Reggio Emilia, Rimini.
Alessia BariDepartment of Diagnostic, Clinical and Public Health Medicine University of Modena and Reggio Emilia, Rimini.
Gabriele BudaDivision of Hematology, University of Pisa, Rimini.
Anna Lia MolinariHematology Unit, Infermi Hospital, Rimini.
Luca BaldiniDepartment of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Piacenza.
Daniele VallisaHematology Unit, Guglielmo da Saliceto Hospital, Piacenza.
Marina CesarettiDepartment of Diagnostic, Clinical and Public Health Medicine University of Modena and Reggio Emilia, Rimini.
Pellegrino MustoHematology and SCT Unit, IRCCS-CROB, Centro di Riferimento Oncologico della Basilicata, Rionero in Vulture, Meldola.
Sonia RonconiHematology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola.
Giorgina SpecchiaUnit of Hematology with Transplantation, Department of Emergency and Organ Transplantation, University of Bari, Reggio Emilia.
Franco SilvestrisDepartment of Biomedical Sciences and Human Oncology, University of Bari "A. Moro", Reggio Emilia.
Luciano GuardigniDivision of Internal Medicine, Cesena Hospital, Hematology Unit, Azienda Ospedaliera Arcispedale Santa Maria Nuova, IRCCS, Reggio Emilia.
Angela Ferrari
Annalisa ChiapellaDepartment of Hematology, Città della Salute e della Scienza Hospital and University of Torino, Genova.
Angelo Michele CarellaHematology Unit, San Martino Hospital, Genova.
Armando SantoroDepartment of Hematology & Oncology, Humanitas Cancer Center, Humanitas Clinical & Research, Rozzano.
Francesco Di RaimondoDivision of Haematology, AOU "Policlinico-Vittorio Emanuele", University of Catania, Italy.
Luigi MarcheselliDepartment of Diagnostic, Clinical and Public Health Medicine University of Modena and Reggio Emilia, Rimini.
Samantha PozziDepartment of Diagnostic, Clinical and Public Health Medicine University of Modena and Reggio Emilia, Rimini.
University of Modena and Reggio Emilia · ITIstituti di Ricovero e Cura a Carattere Scientifico · ITUniversity of Bari Aldo Moro · ITAzienda Ospedaliera Citta' della Salute e della Scienza di Torino · ITAzienda Ospedaliera S.Maria · ITAzienda Ospedaliero-Universitaria Policlinico - Vittorio Emanuele · ITFondazione IRCCS Istituto Nazionale dei Tumori · ITGuglielmo da Saliceto Hospital · ITHumanitas University · ITOspedale Infermi di Rimini · ITOspedale Policlinico San Martino · ITUniversity of Pisa · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AgedAntineoplastic Combined Chemotherapy ProtocolsDisease-Free SurvivalFemaleHumansItalyLenalidomideLymphoma, Non-HodgkinMaleMiddle AgedRituximabSurvival RateThalidomideLenalidomideRituximabThalidomideefficacyindolentlenalidomidenon-follicular lymphomarecurrentrituximabsafety

Identifiers

PMID26858355
PMCPMC5004354
OpenAlexW2268151149

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.